326 related articles for article (PubMed ID: 37326394)
21. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53.
Arena G; Cissé MY; Pyrdziak S; Chatre L; Riscal R; Fuentes M; Arnold JJ; Kastner M; Gayte L; Bertrand-Gaday C; Nay K; Angebault-Prouteau C; Murray K; Chabi B; Koechlin-Ramonatxo C; Orsetti B; Vincent C; Casas F; Marine JC; Etienne-Manneville S; Bernex F; Lombès A; Cameron CE; Dubouchaud H; Ricchetti M; Linares LK; Le Cam L
Mol Cell; 2018 Feb; 69(4):594-609.e8. PubMed ID: 29452639
[TBL] [Abstract][Full Text] [Related]
23. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
24. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
26. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
27. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
28. Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.
Aizu W; Belinsky GS; Flynn C; Noonan EJ; Boes CC; Godman CA; Doshi B; Nambiar PR; Rosenberg DW; Giardina C
Biochem Pharmacol; 2006 Oct; 72(8):981-91. PubMed ID: 16949053
[TBL] [Abstract][Full Text] [Related]
29. Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities.
Yang HY; Wen YY; Lin YI; Pham L; Su CH; Yang H; Chen J; Lee MH
Oncogene; 2007 Nov; 26(52):7355-62. PubMed ID: 17546054
[TBL] [Abstract][Full Text] [Related]
30. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
31. The regulation of MDM2 oncogene and its impact on human cancers.
Zhao Y; Yu H; Hu W
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):180-9. PubMed ID: 24389645
[TBL] [Abstract][Full Text] [Related]
32. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
33. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
35. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
36. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.
Manfredi JJ
Genes Dev; 2010 Aug; 24(15):1580-9. PubMed ID: 20679392
[TBL] [Abstract][Full Text] [Related]
37. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
38. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
39. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
40. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
